TP53 and diffuse large B-cell lymphoma: However, our data do align with previous findings on TP53 alterations, which have been shown to be prognostic of inferior survival in DLBCL.[41–44] Mutations inTP53 were found to be associated with EFS24 in the entire cohort (n = 404, unadjusted, HR, 1.8 [95% CI 1.02–3.13] P = 0.04, adjusted for IPI, HR, 1.93 [95% CI 1.07–3.45] P = 0.03), but did not increase the predicative ability of our signature, most likely because the high risk signature already identified TP53 mutated cases.